Gensight Biologics S.a annual shares outstanding
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Shares Outstanding History (SIGHT)
Gensight Biologics S.a reported 220.3M shares outstanding at the end of fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 220.3M | 95.5M | +76.57% |
| 2024 | 2024-12-31 | 124.8M | 59.5M | +91.05% |
| 2023 | 2023-12-31 | 65.3M | 19.0M | +40.95% |
| 2022 | 2022-12-31 | 46.3M | 35,000 | +0.08% |
| 2021 | 2021-12-31 | 46.3M | 5.4M | +13.27% |
| 2020 | 2020-12-31 | 40.9M | — | — |
Gensight Biologics S.a quarterly shares outstanding
Q4.24
Q4.25
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 220.3M | 97.9M | +79.98% |
| Q4 2024 | 2024-12-31 | 122.4M | — | — |
Gensight Biologics S.a Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Gensight Biologics S.a share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Gensight Biologics S.a used €27,000 to repurchase common stock in fy 2024. Across the latest 4 reported fiscal years, total share repurchases were €624,000.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2024 | 2024-12-31 | €27,000 |
| 2023 | 2023-12-31 | €99,000 |
| 2022 | 2022-12-31 | €193,000 |
| 2021 | 2021-12-31 | €305,000 |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Gensight Biologics S.a shares outstanding trends
Over the last five fiscal years, Gensight Biologics S.a's shares outstanding moved from 40.9M to 220.3M, a change of 179.4M. The latest reported quarter, Q4 2025, shows 220.3M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
reported period-end shares
TickerStat displays period-end common shares from official filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...